Xenetic Biosciences (NASDAQ:XBIO) Shares Pass Above 50 Day Moving Average – Here’s What Happened

Xenetic Biosciences, Inc. (NASDAQ:XBIO) shares passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.88 and traded as high as $3.28. Xenetic Biosciences shares last traded at $3.28, with a volume of 6,690 shares.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Xenetic Biosciences Stock Down 0.3%

The firm has a market cap of $7.51 million, a price-to-earnings ratio of -2.83 and a beta of 2.10. The business has a 50 day moving average price of $2.88 and a 200-day moving average price of $2.84.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) EPS for the quarter. The company had revenue of $0.66 million for the quarter. Xenetic Biosciences had a negative return on equity of 40.62% and a negative net margin of 75.90%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC purchased a new stake in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned approximately 0.60% of Xenetic Biosciences at the end of the most recent quarter. 15.12% of the stock is currently owned by hedge funds and other institutional investors.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.